Systemic Therapy in Early-Stage, Wild-Type Non-Small Cell Lung Cancer: Current Standards and Practical Applications

Recent updates to the NCCN Guidelines® for Non-Small Cell Lung Cancer now include several neoadjuvant and adjuvant immunotherapy-containing regimens for patients with early-stage, wild-type disease. These recommendations are supported by pivotal clinical trials demonstrating improvements in event-free and overall survival. However, many clinicians may be unfamiliar with how to apply these emerging standards in real-world practice, particularly when it comes to identifying appropriate candidates, sequencing treatment, and coordinating care across specialties. This session aims to provide information for the interprofessional oncology care team on how to interpret the latest guideline-based strategies and implement them effectively to optimize outcomes for patients with early-stage NSCLC.

Target Audience

This program is designed to meet the educational needs of the interprofessional oncology care team, including physicians, nurse practitioners, nurses, pharmacists, physician associates, and other health care professionals who treat patients with lung cancer. 

Learning Objectives

Following this activity, participants should be able to:

  • Describe current NCCN Guidelines recommendations for systemic therapy in early-stage, wild-type NSCLC.
  • Evaluate clinical trial evidence supporting the use of neoadjuvant and adjuvant immunotherapy.
  • Apply practical, team-based strategies for integrating immunotherapy into treatment planning for early-stage wild-type NSCLC.

You may also be interested in

Archived NCCN Tumor Boards: New Approaches to the Management of Resectable Non-Small Cell Lung Cancer
In recent years, several new systemic therapy regimens were approved by the FDA as additional neoadjuvant or adjuvant treatment options for eligible patients with resectable NSCLC and included in the NCCN Guidelines for NSCLC. Clinicians need to be aware of the updated treatment recommendations to ensure optimal outcomes for patients with early-stage NSCLC.
Advances in the Treatment of Non-Metastatic Non-Small Cell Lung Cancer
Clinicians should be aware of all the available systemic therapy regimens as well as updated guideline recommendations on biomarker testing and treatment to ensure that patients with non-metastatic NSCLC receive the most appropriate treatments.
NCCN Guidelines® Insights - Non–Small Cell Lung Cancer, Version 7.2025
These NCCN Guidelines Insights discuss recent updates to the NCCN Guidelines, with a focus on systemic therapy options for the treatment of patients with nonmetastatic NSCLC and the corresponding molecular testing considerations.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • Exact Sciences
  • Genentech, a member of the Roche Group
  • Johnson & Johnson

This activity is supported by independent medical education grants from: 

  • AbbVie
  • Boehringer Ingelheim Pharmaceuticals, Inc.
Course summary
Available credit: 
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Course opens: 
12/04/2025
Course expires: 
12/14/2026
Cost:
$0.00
Part of: 
Recorded Presentations from the NCCN 2025 Lung Cancer Congress

Dwight H. Owen, MD, MS
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
 

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

Presenting Faculty

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Dwight H. Owen, MD, MS
AbbVie, Inc.: Grant/Research Support
Amgen Inc.: Non-royalty Payments
AstraZeneca Pharmaceuticals LP: Non-royalty Payments
Bristol Myers Squibb: Grant/Research Support
Genentech, Inc.: Grant/Research Support
Janssen Pharmaceutica Products, LP: Non-royalty Payments
Merck & Co., Inc.: Grant/Research Support
Onc.AI: Grant/Research Support
Palobiofarma LLC: Grant/Research Support
Pfizer Inc.: Grant/Research Support
 

Congress Planning Committee

The faculty listed below have no relevant financial relationships with ineligible companies to disclose.

Michael Seidman, MD

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Charu Aggarwal, MD, MPH
AbbVie, Inc.: Consulting Fee
Arcus Biosciences: Consulting Fee
AstraZeneca Pharmaceuticals LP: Consulting Fee
Boehringer Ingelheim GmbH: Consulting Fee
Daiichi Sankyo, Inc./AstraZeneca Pharmaceuticals LP: Consulting Fee 
Gilead Sciences, Inc.: Consulting Fee
Loxo@Lilly: Consulting Fee
Novocure: Consulting Fee
Merck Sharp & Dohme: Consulting Fee
Pfizer Inc.: Consulting Fee
Sanofi/Regeneron: Consulting Fee
Takeda Pharmaceuticals North America, Inc.: Consulting Fee

Hossein Borghaei, DO, MS
AbbVie, Inc.: Consulting Fee; Scientific Advisor
Amgen Inc.: Consulting Fee; Grant/Research Support; Honoraria; Scientific Advisor
Astellas Pharma US, Inc.: Consulting Fee; Scientific Advisor
AstraZeneca Pharmaceuticals LP: Consulting Fee; Scientific Advisor
Axiom: Consulting Fee; Scientific Advisor
Bayer HealthCare: Consulting Fee; Scientific Advisor
BeiGene: Consulting Fee; Scientific Advisor
BerGenBio: Consulting Fee; Scientific Advisor
BioNTech: Consulting Fee; Scientific Advisor
Boehringer Ingelheim GmbH: Consulting Fee; Scientific Advisor
Bristol Myers Squibb: Consulting Fee; Grant/Research Support; Scientific Advisor
Daiichi- Sankyo Co.: Consulting Fee; Honoraria; Scientific Advisor
Eli Lilly and Company: Consulting Fee; Grant/Research Support; Scientific Advisor
EMD Serono: Consulting Fee; Scientific Advisor
Genentech, Inc.: Consulting Fee; Scientific Advisor
Genmab: Consulting Fee; Scientific Advisor
Gilead Sciences, Inc.: Consulting Fee; Scientific Advisor
Grid Therapeutics: Consulting Fee; Scientific Advisor
Guardant Health: Consulting Fee; Scientific Advisor
Incyte Corporation: Scientific Advisor
Inspirna (formerly RGENIX): Equity Interest/Stock Options; Scientific Advisor
IO Bioetech: Consulting Fee; Scientific Advisor
iTeos Therapeutics: Consulting Fee; Scientific Advisor
Janssen Pharmaceutica Products, LP: Consulting Fee; Honoraria; Scientific Advisor
Jazz Pharmaceuticals Inc.: Consulting Fee; Honoraria; Scientific Advisor
Merck & Co., Inc.: Consulting Fee; Scientific Advisor
Mirati Therapeutics, Inc.: Consulting Fee; Scientific Advisor
Novartis Pharmaceuticals Corporation: Consulting Fee; Scientific Advisor
Novocure: Consulting Fee; Scientific Advisor
Natera: Consulting Fee; Scientific Advisor
Oncocyte: Consulting Fee; Scientific Advisor
PharmaMar: Consulting Fee; Scientific Advisor
Pfizer Inc.: Consulting Fee; Honoraria; Scientific Advisor
Puma Biotechnology: Consulting Fee; Scientific Advisor
RAPT Therapeutics Consulting Fee; Scientific Advisor
Regeneron Pharmaceuticals, Inc.: Consulting Fee; Honoraria; Scientific Advisor
Servier: Scientific Advisor
Sonnet BioTherapeutics, Inc.: Equity Interest/Stock Options; Scientific Advisor
SpringWorks Therapeutics: Scientific Advisor
Summit Therapeutics Consulting Fee; Scientific Advisor
SystImmune, Inc.: Consulting Fee; Scientific Advisor
Takeda Pharmaceuticals North America, Inc.: Consulting Fee; Scientific Advisor

Gregory J. Riely, MD, PhD
Amgen Inc.: Grant/Research Support
Bristol Myers Squibb: Grant/Research Support
Eli Lilly and Company: Grant/Research Support
Merck & Co., Inc.: Grant/Research Support
Novartis Pharmaceuticals Corporation: Grant/Research Support
Pfizer Inc.: Grant/Research Support
Roche Laboratories, Inc.: Grant/Research Support
Takeda Pharmaceuticals North America, Inc.: Grant/Research Support

NCCN Staff Disclosures

None of the other planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 0.5 contact hour. 

Pharmacists
NCCN designates this knowledge-based continuing education activity for 0.5 contact hour (0.05 CEUs) of continuing education credit. UAN: JA4008196-0000-25-148-H01-P

Physician Associates
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification (MOC)
 

 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Aggregated participant data will be shared with the commercial supporters of this activity.

American Board of Pathology Continuing Certification (CC)
 

This activity has been registered to offer credit in the American Board of Pathology’s (ABPath) Continuing Certification program. Participants may earn up to 0.5 Lifelong Learning (Part II) credit.

Aggregated participant data will be shared with the commercial supporters of this activity.

American Board of Surgery Continuous Certification (CC)
 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME requirements of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

American Board of Thoracic Surgery (CC)
Successful completion of this CME activity enables the learner to earn credit toward the CME requirements of the American Board of Thoracic Surgery’s Continuing Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABTS credit.

American Board of Medical Specialties (MOC)
Through the American Board of Medical Specialties (“ABMS”) MOC Initiative to create a wide array of Maintenance of Certification (“MOC”) Activities through the ABMS MOC Directory, the NCCN 2025 Lung Cancer Congress has met the MOC requirements as a MOC Part II CME Activity (apply toward general CME requirement) by the following ABMS Member Boards:

MOC Part II CME Activity
Radiology

Permission to Upload Credits
For ABIM, ABPath, ABS, and ABTS MOC points, your information will be shared with your board through NCCN's Joint Accreditation Program and Activity Reporting System (JA-PARS). Please allow 6-8 weeks for your MOC points to appear on your board records.

By sharing your Diplomate Board ID # and DOB, you are giving NCCN permission to use this information/data to report your participation to these boards via JA-PARS.

Available Credit

  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing